title: Frequency and significance of antibodies to asialoglycoprotein receptor in type 1 autoimmune hepatitis.
abstract: Antibodies to asialoglycoprotein receptor have diagnostic specificity for autoimmune hepatitis, but it is uncertain if they are complementary or redundant markers of the disease. Our aims were to assess their frequency and significance in type 1 autoimmune hepatitis and determine their contribution to the evaluation of these patients. Sera from 54 well-characterized patients were evaluated for antibodies to asialoglycoprotein receptor by a radioimmunofiltration assay based on rabbit-derived protein. Forty-four patients (82%) were seropositive. Seropositive patients were distinguished from seronegative counterparts by having higher serum gamma globulin (3.7 +/- 0.2 g/dl vs 2.3 +/- 0.3 g/dl, P = 0.0007) and immunoglobulin G levels (3707 +/- 179 mg/dl vs 2203 +/- 263 mg/dl, P = 0.0005) at presentation and a greater frequency of relapse after drug withdrawal (88% vs 33%, P = 0.01). Seropositivity for smooth muscle and/or antinuclear antibodies did not define treatment outcomes and antinuclear antibodies occurred less frequently than the other markers. Concurrent testing for antibodies to asialoglycoprotein receptor and smooth muscle identified all patients. We conclude that antibodies to asialoglycoprotein receptor are common in type 1 autoimmune hepatitis and they identify patients with a high frequency of relapse after corticosteroid withdrawal. Concurrent testing for these antibodies and smooth muscle antibodies has the same diagnostic sensitivity as testing for antinuclear and smooth muscle antibodies but a greater prognostic implication.
authors.affiliation: Division of Gastroenterology and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA.
authors.forename: A J
authors.initials: AJ
authors.lastname: Czaja
authors.forename: K D
authors.initials: KD
authors.lastname: Pfeifer
authors.forename: R H
authors.initials: RH
authors.lastname: Decker
authors.forename: A S
authors.initials: AS
authors.lastname: Vallari
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000906:Antibodies / Q000097:blood*; D000974:Antibodies, Antinuclear / Q000097:blood; D037263:Asialoglycoprotein Receptor; D001212:Asialoglycoproteins / Q000276:immunology; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000276:immunology*; D015415:Biomarkers / Q000097:blood; D005260:Female; D006505:Hepatitis / Q000188:drug therapy / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011956:Receptors, Cell Surface / Q000276:immunology*
chemical_list: D000305:Adrenal Cortex Hormones; D000906:Antibodies; D000974:Antibodies, Antinuclear; D037263:Asialoglycoprotein Receptor; D001212:Asialoglycoproteins; D015415:Biomarkers; D007074:Immunoglobulin G; D011956:Receptors, Cell Surface